Endotoxin, TLR4 signaling and vascular inflammation: Potential therapeutic targets in cardiovascular disease

Lynn L. Stoll, Gerene M. Denning, Neal Lee Weintraub

Research output: Contribution to journalReview article

90 Citations (Scopus)

Abstract

Cardiovascular disease ranks among the leading causes of morbidity and mortality in adult populations in the Western world. Significant progress in understanding the etiology of cardiovascular disease has come from recent recognition that chronic inflammation plays a key role in its development. The principal mediators of this inflammatory response, and the mechanisms by which they work, however, are incompletely understood. Moreover, the complex nature of the inflammatory response poses significant challenges to the development of effective and targeted treatments. Potentially promising targets to reduce inflammation in atherosclerosis include Toll-like receptor (TLR) pathways and anti-inflammatory factors that modulate TLR signaling. In this review, we outline studies that provide insight into the links between cardiovascular disease and inflammation, focusing on innate immunity and endotoxin/TLR4 signaling. We also discuss the contribution of specific host immune/inflammatory responses to atherogenesis, and describe cellular signaling pathways (lipopolysaccharide-binding protein [LBP], CD14, MD-2, TLR4, MyD88, and NF-κB, among others) that play key roles in innate immune signaling. Finally, we discuss the therapeutic potential of modulating these cellular signaling pathways as future strategies for the prevention and treatment of cardiovascular disease, including such approaches as specific targeting of the TLR4 signaling pathway, antibiotic therapy, drug classes with broad anti- inflammatory activity (statins, thiazolidinediones), and the potential of vaccine development. Because of the complexity of the links between low-level chronic infections, inflammation, and atherosclerosis, treatment and prevention of cardiovascular disease will likely require an integrated approach that utilizes a combination of these strategies to target the underlying inflammatory processes.

Original languageEnglish (US)
Pages (from-to)4229-4245
Number of pages17
JournalCurrent Pharmaceutical Design
Volume12
Issue number32
DOIs
StatePublished - Nov 1 2006
Externally publishedYes

Fingerprint

Endotoxins
Blood Vessels
Cardiovascular Diseases
Inflammation
Atherosclerosis
Toll-Like Receptors
Anti-Inflammatory Agents
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Thiazolidinediones
Western World
Innate Immunity
Vaccines
Anti-Bacterial Agents
Morbidity
Drug Therapy
Mortality
Infection
Population

Keywords

  • Atherogenesis
  • CD14 expression
  • Chemokines
  • Endotoxin
  • LPS Binding Protein (LPB)
  • TLR4 receptor complex

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Endotoxin, TLR4 signaling and vascular inflammation : Potential therapeutic targets in cardiovascular disease. / Stoll, Lynn L.; Denning, Gerene M.; Weintraub, Neal Lee.

In: Current Pharmaceutical Design, Vol. 12, No. 32, 01.11.2006, p. 4229-4245.

Research output: Contribution to journalReview article

@article{14851ee232b146538aed5df7dff70400,
title = "Endotoxin, TLR4 signaling and vascular inflammation: Potential therapeutic targets in cardiovascular disease",
abstract = "Cardiovascular disease ranks among the leading causes of morbidity and mortality in adult populations in the Western world. Significant progress in understanding the etiology of cardiovascular disease has come from recent recognition that chronic inflammation plays a key role in its development. The principal mediators of this inflammatory response, and the mechanisms by which they work, however, are incompletely understood. Moreover, the complex nature of the inflammatory response poses significant challenges to the development of effective and targeted treatments. Potentially promising targets to reduce inflammation in atherosclerosis include Toll-like receptor (TLR) pathways and anti-inflammatory factors that modulate TLR signaling. In this review, we outline studies that provide insight into the links between cardiovascular disease and inflammation, focusing on innate immunity and endotoxin/TLR4 signaling. We also discuss the contribution of specific host immune/inflammatory responses to atherogenesis, and describe cellular signaling pathways (lipopolysaccharide-binding protein [LBP], CD14, MD-2, TLR4, MyD88, and NF-κB, among others) that play key roles in innate immune signaling. Finally, we discuss the therapeutic potential of modulating these cellular signaling pathways as future strategies for the prevention and treatment of cardiovascular disease, including such approaches as specific targeting of the TLR4 signaling pathway, antibiotic therapy, drug classes with broad anti- inflammatory activity (statins, thiazolidinediones), and the potential of vaccine development. Because of the complexity of the links between low-level chronic infections, inflammation, and atherosclerosis, treatment and prevention of cardiovascular disease will likely require an integrated approach that utilizes a combination of these strategies to target the underlying inflammatory processes.",
keywords = "Atherogenesis, CD14 expression, Chemokines, Endotoxin, LPS Binding Protein (LPB), TLR4 receptor complex",
author = "Stoll, {Lynn L.} and Denning, {Gerene M.} and Weintraub, {Neal Lee}",
year = "2006",
month = "11",
day = "1",
doi = "10.2174/138161206778743501",
language = "English (US)",
volume = "12",
pages = "4229--4245",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "32",

}

TY - JOUR

T1 - Endotoxin, TLR4 signaling and vascular inflammation

T2 - Potential therapeutic targets in cardiovascular disease

AU - Stoll, Lynn L.

AU - Denning, Gerene M.

AU - Weintraub, Neal Lee

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Cardiovascular disease ranks among the leading causes of morbidity and mortality in adult populations in the Western world. Significant progress in understanding the etiology of cardiovascular disease has come from recent recognition that chronic inflammation plays a key role in its development. The principal mediators of this inflammatory response, and the mechanisms by which they work, however, are incompletely understood. Moreover, the complex nature of the inflammatory response poses significant challenges to the development of effective and targeted treatments. Potentially promising targets to reduce inflammation in atherosclerosis include Toll-like receptor (TLR) pathways and anti-inflammatory factors that modulate TLR signaling. In this review, we outline studies that provide insight into the links between cardiovascular disease and inflammation, focusing on innate immunity and endotoxin/TLR4 signaling. We also discuss the contribution of specific host immune/inflammatory responses to atherogenesis, and describe cellular signaling pathways (lipopolysaccharide-binding protein [LBP], CD14, MD-2, TLR4, MyD88, and NF-κB, among others) that play key roles in innate immune signaling. Finally, we discuss the therapeutic potential of modulating these cellular signaling pathways as future strategies for the prevention and treatment of cardiovascular disease, including such approaches as specific targeting of the TLR4 signaling pathway, antibiotic therapy, drug classes with broad anti- inflammatory activity (statins, thiazolidinediones), and the potential of vaccine development. Because of the complexity of the links between low-level chronic infections, inflammation, and atherosclerosis, treatment and prevention of cardiovascular disease will likely require an integrated approach that utilizes a combination of these strategies to target the underlying inflammatory processes.

AB - Cardiovascular disease ranks among the leading causes of morbidity and mortality in adult populations in the Western world. Significant progress in understanding the etiology of cardiovascular disease has come from recent recognition that chronic inflammation plays a key role in its development. The principal mediators of this inflammatory response, and the mechanisms by which they work, however, are incompletely understood. Moreover, the complex nature of the inflammatory response poses significant challenges to the development of effective and targeted treatments. Potentially promising targets to reduce inflammation in atherosclerosis include Toll-like receptor (TLR) pathways and anti-inflammatory factors that modulate TLR signaling. In this review, we outline studies that provide insight into the links between cardiovascular disease and inflammation, focusing on innate immunity and endotoxin/TLR4 signaling. We also discuss the contribution of specific host immune/inflammatory responses to atherogenesis, and describe cellular signaling pathways (lipopolysaccharide-binding protein [LBP], CD14, MD-2, TLR4, MyD88, and NF-κB, among others) that play key roles in innate immune signaling. Finally, we discuss the therapeutic potential of modulating these cellular signaling pathways as future strategies for the prevention and treatment of cardiovascular disease, including such approaches as specific targeting of the TLR4 signaling pathway, antibiotic therapy, drug classes with broad anti- inflammatory activity (statins, thiazolidinediones), and the potential of vaccine development. Because of the complexity of the links between low-level chronic infections, inflammation, and atherosclerosis, treatment and prevention of cardiovascular disease will likely require an integrated approach that utilizes a combination of these strategies to target the underlying inflammatory processes.

KW - Atherogenesis

KW - CD14 expression

KW - Chemokines

KW - Endotoxin

KW - LPS Binding Protein (LPB)

KW - TLR4 receptor complex

UR - http://www.scopus.com/inward/record.url?scp=33750537650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750537650&partnerID=8YFLogxK

U2 - 10.2174/138161206778743501

DO - 10.2174/138161206778743501

M3 - Review article

C2 - 17100625

AN - SCOPUS:33750537650

VL - 12

SP - 4229

EP - 4245

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 32

ER -